샘플 요청 목록

 카트 문의
시장보고서
상품코드
1744805

세계의 경구 항바이러스제 시장

Oral Antivirals
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 380 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 경구 항바이러스제 시장은 2030년까지 390억 달러에 달할 전망

2024년에 357억 달러로 추정되는 세계의 경구 항바이러스제 시장은 2024-2030년의 분석 기간에 CAGR 1.5%로 성장하며, 2030년에는 390억 달러에 달할 것으로 예측됩니다. 이 리포트에서 분석한 부문의 하나인 인간면역결핍바이러스 적응증은 CAGR 1.0%를 기록하며, 분석 기간 종료까지 180억 달러에 달할 것으로 예측됩니다. 간염 치료제 부문의 성장률은 분석 기간 중 CAGR 2.1%로 추정됩니다.

미국 시장은 97억 달러로 추정, 중국은 CAGR 2.8%로 성장 예측

미국의 경구 항바이러스제 시장은 2024년에 97억 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 2030년까지 71억 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년의 CAGR은 2.8%입니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 0.6%와 1.2%로 예측됩니다. 유럽에서는 독일이 CAGR 약 0.8%로 성장할 것으로 예측됩니다.

세계의 경구 항바이러스제 시장 - 주요 동향과 촉진요인 정리

경구용 항바이러스제, 감염병 관리의 전망을 재구성하다?

경구용 항바이러스제 - 숙주세포내 바이러스 복제를 억제하는 경구용 약물 - 는 현대 항바이러스 치료의 핵심으로 부상하고 있습니다. 의료기관에서 투여해야 하는 주사용 항바이러스제와 달리 경구용 항바이러스제는 편의성, 확장성, 외래 투약이 가능해 공중보건 위기 상황이나 만성 바이러스성 질환에 매우 중요합니다. 독감, 간염, HIV, 헤르페스, 그리고 최근 COVID-19에 이르기까지 경구용 항바이러스제는 다양한 바이러스 병원체에서 임상적, 상업적 성공을 거둔 바 있습니다.

COVID-19 팬데믹은 전 세계 경구용 항바이러스제의 실험장이 되었고, 몰누피라비르와 닐마트루비르/리토나비어(POVID)와 같은 분자가 바이러스 양, 입원율, 감염 위험을 줄이기 위해 대규모로 배포되었습니다. 이러한 치료제는 팬데믹 대응에 있으며, 비축, 조기 개입, 지역사회 기반 제공의 전략적 중요성을 강조하고 있습니다. 이러한 약물의 성공은 제약 대기업과 바이오테크 스타트업 모두 호흡기, 신경 영양, 출혈성 바이러스를 표적으로 하는 경구용 치료제 개발 파이프라인을 가속화하고 있습니다.

왜 광범위 약물과 내성 방지 메커니즘이 요구되는가?

바이러스의 변이가 치료 효과에 끊임없는 도전을 던지고 있으며, 보존된 바이러스를 표적으로 작용하는 광범위 경구용 항바이러스제에 대한 수요가 증가하고 있습니다. 중합효소 억제제, 프로테아제 억제제, 엔트리 억제제는 여러 균주 및 종에 대해 교차 바이러스 활성을 나타내도록 설계되었습니다. 이러한 치료제는 병원체 특정 진단에 대한 의존도를 줄이고 치료 요법을 단순화할 수 있습니다.

항바이러스제 내성 위험을 줄이기 위해 약물 개발자들은 내성에 대한 유전적 장벽이 높은 약물을 설계하고, 선택 압력을 줄이는 병용요법을 모색하고 있습니다. 바이러스 복제에 필수적인 숙주 경로를 방해하는 숙주 지향성 항바이러스제는 범바이러스성 가능성으로 인해 지지를 받고 있습니다. 또한 HIV나 HBV와 같은 만성질환에 대해 1일 1회 경구투여를 가능하게 하는 한편, 생체 이용률, 조직 침투성, 치료범위를 개선하기 위해 프로드러그 제제나 약동학 개선제가 사용되고 있습니다.

기술 플랫폼과 시장 진출 전략은 어떻게 치료 영역을 확장하고 있는가?

구조 기반 약물 설계, AI를 활용한 화합물 스크리닝, 고처리량 바이러스 분석의 등장으로 새로운 경구용 항바이러스제 후보물질의 발굴이 가속화되고 있습니다. 기업 개요은 최적의 약력학 및 안전성 프로파일을 가진 분자를 설계하기 위해 머신러닝과 in silico 모델링을 활용하고 있습니다. 경구용 항바이러스제는 또한 나노입자 담체, 장용성 코팅, 서방형 제제 등 고형 제제 기술의 발전으로 흡수율과 환자 순응도를 향상시키고 있습니다.

자발적 라이선스, 단계적 가격 책정, 공공-민간 파트너십과 같은 세계 접근 전략은 중저소득 국가(LMICs)에서 경구용 항바이러스제의 제조 및 유통을 확대하는 데 도움이 되고 있습니다. 메디신 특허 풀(Medicine Patent Pool)이나 UNITAID와 같은 조직은 항바이러스 치료제가 충분하지 않은 지역에서도 COVID-19 항바이러스제를 이용할 수 있도록 하는 데 중요한 역할을 하고 있습니다. 각국 정부가 항바이러스제 비축과 팬데믹 대응을 위해 투자하는 가운데, 경구용 항바이러스제는 배포가 용이하다는 점에서 조달 전략의 우선순위가 되고 있습니다.

경구용 항바이러스 치료제의 세계 수요 증가 원동력은?

경구용 항바이러스제 시장의 성장은 바이러스성 질병 부담 증가, 외래 및 재택 치료 모델로의 전환, 팬데믹 대비 노력에 의해 주도되고 있습니다. 주요 성장 요인은 바이러스 발생시 의료비 부담과 사망률을 줄이기 위한 확장 가능한 초기 단계의 항바이러스 개입에 대한 전 세계적인 수요입니다. 인수공통전염병 바이러스의 출현, 항바이러스제 내성 증가, 미래의 팬데믹(세계적 대유행) 위험으로 인해 각국 정부와 의료 기관은 신속한 대응을 위한 항바이러스제 포트폴리오에 투자하고 있습니다.

HIV, B형 간염, C형 간염, 헤르페스 감염과 같은 만성 바이러스 질환은 독성이 낮고 순응도를 향상시키면서 장기적인 바이러스 억제를 가능하게 하는 경구용 항바이러스제에 대한 지속적인 수요를 창출하고 있습니다. 한편, 원격의료, 디지털 약국, 분산형 임상시험의 성장으로 경구용 항바이러스 치료제의 신속한 진단, 처방, 모니터링이 가능해지고 있습니다.

R&D 투자 확대, 긴급사용에 대한 규제 당국의 지원, 잠재적 대유행 바이러스 병원체를 표적으로 하는 강력한 파이프라인으로 인해 경구용 항바이러스제 시장은 강력한 성장세를 보이고 있습니다. 이러한 치료법은 기존 감염성 질환의 치료 패러다임을 변화시킬 뿐만 아니라 미래의 바이러스 위협에 대한 세계 보건의 강인성을 강화할 수 있습니다.

부문

적응증(인간면역결핍바이러스, 간염, 인플루엔자, 기타 적응증);판매채널(드러그스토어·소매 약국, 병원 약국, 온라인 프로바이더);약제 클래스(역전사 효소 저해제, 프로테아제 저해제, 기타 약제 클래스별)

조사 대상 기업의 예(주목 44사)

  • AbbVie Inc.
  • Amneal Pharmaceuticals LLC
  • Aurobindo Pharma Ltd.
  • BioCryst Pharmaceuticals Inc.
  • Bristol-Myers Squibb Co.
  • Cipla Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Enanta Pharmaceuticals Inc.
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences Inc.
  • GlaxoSmithKline plc(GSK)
  • Hetero Labs Ltd.
  • Johnson & Johnson
  • Lupin Pharmaceuticals Ltd.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Shionogi & Co., Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.

관세 영향 계수

Global Industry Analysts는 본사의 국가, 제조거점, 수출입(완제품 및 OEM)을 기반으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 인위적인 수입원가 증가, 수익성 감소, 공급망 재편 등 미시적 및 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

Global Industry Analysts는 세계 주요 수석 이코노미스트(1,4,949명), 싱크탱크(62개 기관), 무역 및 산업 단체(171개 기관)의 전문가들의 의견을 면밀히 검토하여 생태계에 미치는 영향을 평가하고 새로운 시장 현실에 대응하고 있습니다. 모든 주요 국가의 전문가와 경제학자들이 관세와 그것이 자국에 미치는 영향에 대한 의견을 추적 조사했습니다.

Global Industry Analysts는 이러한 혼란이 향후 2-3개월 내에 마무리되고 새로운 세계 질서가 보다 명확하게 확립될 것으로 예상하고 있으며, Global Industry Analysts는 이러한 상황을 실시간으로 추적하고 있습니다.

2025년 4월: 협상 단계

이번 4월 보고서에서는 관세가 세계 시장 전체에 미치는 영향과 지역별 시장 조정에 대해 소개합니다. 당사의 예측은 과거 데이터와 진화하는 시장 영향요인을 기반으로 합니다.

2025년 7월: 최종 관세 재설정

고객님들께는 각 국가별 최종 리셋이 발표된 후 7월에 무료 업데이트 버전을 제공해 드립니다. 최종 업데이트 버전에는 명확하게 정의된 관세 영향 분석이 포함되어 있습니다.

상호 및 양자 간 무역과 관세의 영향 분석 :

미국 <gt; 중국 <gt; 멕시코 <gt; 캐나다 <gt;EU <gt; 일본 <gt; 인도 <gt; 기타 176개국

업계 최고의 이코노미스트: Global Industry Analysts의 지식 기반은 국가, 싱크탱크, 무역 및 산업 단체, 대기업, 그리고 세계 계량 경제 상황의 전례 없는 패러다임 전환의 영향을 공유하는 분야별 전문가 등 가장 영향력 있는 수석 이코노미스트 그룹을 포함한 14,949명의 이코노미스트를 추적하고 있습니다. 16,491개 이상의 보고서 대부분에 마일스톤에 기반한 2단계 출시 일정을 적용하고 있습니다.

목차

제1장 조사 방법

제2장 개요

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSA 25.06.20

Global Oral Antivirals Market to Reach US$39.0 Billion by 2030

The global market for Oral Antivirals estimated at US$35.7 Billion in the year 2024, is expected to reach US$39.0 Billion by 2030, growing at a CAGR of 1.5% over the analysis period 2024-2030. Human Immunodeficiency Virus Indication, one of the segments analyzed in the report, is expected to record a 1.0% CAGR and reach US$18.0 Billion by the end of the analysis period. Growth in the Hepatitis Indication segment is estimated at 2.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$9.7 Billion While China is Forecast to Grow at 2.8% CAGR

The Oral Antivirals market in the U.S. is estimated at US$9.7 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$7.1 Billion by the year 2030 trailing a CAGR of 2.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.6% and 1.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 0.8% CAGR.

Global Oral Antivirals Market - Key Trends & Drivers Summarized

Are Oral Antiviral Therapies Reshaping the Landscape of Infectious Disease Management?

Oral antivirals-drugs formulated for oral administration that inhibit the replication of viruses inside host cells-have emerged as a cornerstone of modern antiviral therapy. Unlike injectable antivirals that require healthcare administration, oral formulations provide convenience, scalability, and outpatient suitability-qualities that are critical during public health crises and for chronic viral conditions. From influenza and hepatitis to HIV, herpes, and most recently COVID-19, oral antivirals are demonstrating clinical and commercial success across diverse viral pathogens.

The COVID-19 pandemic served as a global proving ground for oral antivirals, with molecules like molnupiravir and nirmatrelvir/ritonavir (Paxlovid) being deployed at scale to reduce viral load, hospitalization rates, and transmission risk. These treatments highlighted the strategic importance of stockpiling, early intervention, and community-based delivery in pandemic preparedness. The success of these agents is encouraging both pharmaceutical giants and biotech startups to accelerate development pipelines targeting respiratory, neurotropic, and hemorrhagic viruses with oral therapies.

Why Are Broad-Spectrum Agents and Resistance-Proof Mechanisms in High Demand?

With viral mutation posing a constant challenge to therapeutic efficacy, there is a growing demand for broad-spectrum oral antivirals that act on conserved viral targets. Polymerase inhibitors, protease inhibitors, and entry inhibitors are being engineered for cross-viral activity against multiple strains and species. Such drugs reduce the reliance on pathogen-specific diagnostics and simplify treatment regimens-especially in regions with limited laboratory infrastructure.

To mitigate the risk of antiviral resistance, drug developers are designing agents with high genetic barriers to resistance and exploring combination therapies that reduce selective pressure. Host-directed antivirals, which interfere with host pathways essential to viral replication, are gaining traction due to their pan-viral potential. Additionally, prodrug formulations and pharmacokinetic enhancers are being used to improve bioavailability, tissue penetration, and therapeutic window while enabling once-daily oral dosing for chronic conditions like HIV and HBV.

How Are Technology Platforms and Market Access Strategies Expanding the Therapeutic Reach?

The advent of structure-based drug design, AI-driven compound screening, and high-throughput viral assays is accelerating the identification of novel oral antiviral candidates. Pharmaceutical companies are leveraging machine learning and in silico modeling to design molecules with optimal pharmacodynamics and safety profiles. Oral antivirals are also benefiting from advancements in solid dosage form technologies such as nanoparticle carriers, enteric coatings, and sustained-release formulations to enhance absorption and patient compliance.

Global access strategies-including voluntary licensing, tiered pricing, and public-private partnerships-are helping scale up manufacturing and distribution of oral antivirals in low- and middle-income countries (LMICs). Organizations like Medicines Patent Pool and UNITAID are playing a key role in making COVID-19 antivirals accessible across regions previously underserved by antiviral therapy. As governments invest in antiviral stockpiling and pandemic readiness, oral antivirals are being prioritized in procurement strategies due to their ease of deployment.

What’s Driving the Growing Demand for Oral Antiviral Therapeutics Globally?

The growth in the oral antivirals market is driven by rising viral disease burden, the shift toward outpatient and home-based treatment models, and pandemic preparedness initiatives. A primary growth driver is the global need for scalable, early-stage antiviral interventions that reduce healthcare strain and mortality in viral outbreaks. The emergence of zoonotic viruses, increasing antiviral resistance, and the risk of future pandemics are compelling governments and health systems to invest in rapid-response antiviral portfolios.

Chronic viral conditions such as HIV, hepatitis B and C, and herpes simplex infections continue to generate sustained demand for oral antivirals that combine long-term viral suppression with low toxicity and improved adherence. Meanwhile, the growth of telemedicine, digital pharmacies, and decentralized clinical trials is enabling faster diagnosis, prescription, and monitoring of oral antiviral therapy.

With growing R&D investments, regulatory support for emergency use, and a strong pipeline targeting viral pathogens of pandemic potential, the oral antivirals market is poised for robust expansion. These therapies are not only transforming the treatment paradigm for existing infections but also reinforcing global health resilience against future viral threats.

SCOPE OF STUDY:

The report analyzes the Oral Antivirals market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Indication (Human Immunodeficiency Virus, Hepatitis, Influenza, Other Indications); Distribution Channel (Drug Stores & Retail Pharmacies, Hospital Pharmacies, Online Providers); Drug Class (Reverse Transcriptase Inhibitors, Protease Inhibitors, Other Drug Classes)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

  • AbbVie Inc.
  • Amneal Pharmaceuticals LLC
  • Aurobindo Pharma Ltd.
  • BioCryst Pharmaceuticals Inc.
  • Bristol-Myers Squibb Co.
  • Cipla Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Enanta Pharmaceuticals Inc.
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences Inc.
  • GlaxoSmithKline plc (GSK)
  • Hetero Labs Ltd.
  • Johnson & Johnson
  • Lupin Pharmaceuticals Ltd.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Shionogi & Co., Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Oral Antivirals - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Viral Infections Drives Global Demand for Broad-Spectrum Oral Antivirals
    • Expansion of Pandemic Preparedness Programs Throws the Spotlight on Scalable Oral Antiviral Stockpiles
    • OEM Innovation in Nucleoside and Protease Inhibitors Strengthens Pipeline of Small-Molecule Therapies
    • Regulatory Approvals for COVID-19 Oral Antivirals Accelerate Market Acceptance and Infrastructure Investment
    • Growth in Antiviral Use for Influenza, Hepatitis, and Herpes Simplex Supports Therapeutic Portfolio Expansion
    • OEM Partnerships With Academic Institutions Enhance Discovery of Novel Antiviral Compounds
    • Increased Focus on Antiviral Resistance Drives Development of Combination Oral Regimens
    • Emergence of Host-Targeted Antivirals Expands Scope for Long-Term Disease Suppression
    • OEM Investment in Oral Prodrug Technologies Enhances Bioavailability and Dosing Convenience
    • Global Support for Equitable Access to Oral Therapies Promotes Expansion in Low- and Middle-Income Countries
    • Regulatory Incentives for Orphan and Rare Viral Diseases Propel Clinical Development Pipelines
    • Rising Use in Prophylaxis and Post-Exposure Scenarios Strengthens Adoption in High-Risk Populations
    • OEM Focus on Rapid Onboarding and At-Home Treatment Modalities Drives Patient-Centered Drug Design
    • Growth in Direct-to-Patient Telehealth Platforms Supports Remote Prescription and Dispensation of Oral Antivirals
    • OEM Advances in Resistance Profiling and Companion Diagnostics Enable Personalized Antiviral Therapy
    • Expansion of Pediatric and Geriatric Formulations Broadens Age-Specific Treatment Adoption
    • Government Stockpiling for Biodefense and Outbreak Response Enhances Market Stability
    • OEM Emphasis on Thermostable and Shelf-Stable Formulations Facilitates Deployment in Remote Regions
    • Growing Role of AI in Antiviral Molecule Screening Accelerates Drug Discovery Timelines
    • Strategic Licensing and Global Procurement Agreements Drive Competitive Market Dynamics
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Oral Antivirals Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Oral Antivirals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Oral Antivirals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Oral Antivirals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Human Immunodeficiency Virus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Human Immunodeficiency Virus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Human Immunodeficiency Virus by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Hepatitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Hepatitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Hepatitis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Influenza by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Influenza by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Influenza by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Reverse Transcriptase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Reverse Transcriptase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Reverse Transcriptase Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Protease Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Protease Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Protease Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Drug Stores & Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Drug Stores & Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Drug Stores & Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Online Providers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Online Providers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Online Providers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Oral Antivirals Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 35: USA Recent Past, Current & Future Analysis for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: USA 15-Year Perspective for Oral Antivirals by Indication - Percentage Breakdown of Value Sales for Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: USA 15-Year Perspective for Oral Antivirals by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors for the Years 2015, 2025 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: USA 15-Year Perspective for Oral Antivirals by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Canada 15-Year Perspective for Oral Antivirals by Indication - Percentage Breakdown of Value Sales for Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Canada 15-Year Perspective for Oral Antivirals by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors for the Years 2015, 2025 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Canada 15-Year Perspective for Oral Antivirals by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • JAPAN
    • Oral Antivirals Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Japan 15-Year Perspective for Oral Antivirals by Indication - Percentage Breakdown of Value Sales for Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Japan 15-Year Perspective for Oral Antivirals by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors for the Years 2015, 2025 & 2030
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Japan 15-Year Perspective for Oral Antivirals by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • CHINA
    • Oral Antivirals Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 62: China Recent Past, Current & Future Analysis for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: China 15-Year Perspective for Oral Antivirals by Indication - Percentage Breakdown of Value Sales for Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 65: China Recent Past, Current & Future Analysis for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: China 15-Year Perspective for Oral Antivirals by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors for the Years 2015, 2025 & 2030
    • TABLE 68: China Recent Past, Current & Future Analysis for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: China 15-Year Perspective for Oral Antivirals by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • EUROPE
    • Oral Antivirals Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Oral Antivirals by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Oral Antivirals by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Europe 15-Year Perspective for Oral Antivirals by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Europe 15-Year Perspective for Oral Antivirals by Indication - Percentage Breakdown of Value Sales for Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Europe 15-Year Perspective for Oral Antivirals by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors for the Years 2015, 2025 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Europe 15-Year Perspective for Oral Antivirals by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • FRANCE
    • Oral Antivirals Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 83: France Recent Past, Current & Future Analysis for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: France 15-Year Perspective for Oral Antivirals by Indication - Percentage Breakdown of Value Sales for Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: France 15-Year Perspective for Oral Antivirals by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors for the Years 2015, 2025 & 2030
    • TABLE 89: France Recent Past, Current & Future Analysis for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: France 15-Year Perspective for Oral Antivirals by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • GERMANY
    • Oral Antivirals Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Germany 15-Year Perspective for Oral Antivirals by Indication - Percentage Breakdown of Value Sales for Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Germany 15-Year Perspective for Oral Antivirals by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors for the Years 2015, 2025 & 2030
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Germany 15-Year Perspective for Oral Antivirals by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Italy 15-Year Perspective for Oral Antivirals by Indication - Percentage Breakdown of Value Sales for Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Italy 15-Year Perspective for Oral Antivirals by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors for the Years 2015, 2025 & 2030
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Italy 15-Year Perspective for Oral Antivirals by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Oral Antivirals Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 110: UK Recent Past, Current & Future Analysis for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: UK 15-Year Perspective for Oral Antivirals by Indication - Percentage Breakdown of Value Sales for Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 113: UK Recent Past, Current & Future Analysis for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: UK 15-Year Perspective for Oral Antivirals by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors for the Years 2015, 2025 & 2030
    • TABLE 116: UK Recent Past, Current & Future Analysis for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: UK 15-Year Perspective for Oral Antivirals by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 119: Spain Recent Past, Current & Future Analysis for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Spain Historic Review for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: Spain 15-Year Perspective for Oral Antivirals by Indication - Percentage Breakdown of Value Sales for Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Spain 15-Year Perspective for Oral Antivirals by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors for the Years 2015, 2025 & 2030
    • TABLE 125: Spain Recent Past, Current & Future Analysis for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Spain Historic Review for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Spain 15-Year Perspective for Oral Antivirals by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 128: Russia Recent Past, Current & Future Analysis for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Russia Historic Review for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Russia 15-Year Perspective for Oral Antivirals by Indication - Percentage Breakdown of Value Sales for Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Russia 15-Year Perspective for Oral Antivirals by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors for the Years 2015, 2025 & 2030
    • TABLE 134: Russia Recent Past, Current & Future Analysis for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Russia Historic Review for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Russia 15-Year Perspective for Oral Antivirals by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Rest of Europe 15-Year Perspective for Oral Antivirals by Indication - Percentage Breakdown of Value Sales for Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Rest of Europe 15-Year Perspective for Oral Antivirals by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors for the Years 2015, 2025 & 2030
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Rest of Europe 15-Year Perspective for Oral Antivirals by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Oral Antivirals Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Oral Antivirals by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Oral Antivirals by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Asia-Pacific 15-Year Perspective for Oral Antivirals by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 15-Year Perspective for Oral Antivirals by Indication - Percentage Breakdown of Value Sales for Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 15-Year Perspective for Oral Antivirals by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors for the Years 2015, 2025 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Asia-Pacific 15-Year Perspective for Oral Antivirals by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Oral Antivirals Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 158: Australia Recent Past, Current & Future Analysis for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Australia Historic Review for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Australia 15-Year Perspective for Oral Antivirals by Indication - Percentage Breakdown of Value Sales for Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Australia 15-Year Perspective for Oral Antivirals by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors for the Years 2015, 2025 & 2030
    • TABLE 164: Australia Recent Past, Current & Future Analysis for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Australia Historic Review for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Australia 15-Year Perspective for Oral Antivirals by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • INDIA
    • Oral Antivirals Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 167: India Recent Past, Current & Future Analysis for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: India Historic Review for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: India 15-Year Perspective for Oral Antivirals by Indication - Percentage Breakdown of Value Sales for Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 170: India Recent Past, Current & Future Analysis for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: India 15-Year Perspective for Oral Antivirals by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors for the Years 2015, 2025 & 2030
    • TABLE 173: India Recent Past, Current & Future Analysis for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: India Historic Review for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: India 15-Year Perspective for Oral Antivirals by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 176: South Korea Recent Past, Current & Future Analysis for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: South Korea Historic Review for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: South Korea 15-Year Perspective for Oral Antivirals by Indication - Percentage Breakdown of Value Sales for Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: South Korea 15-Year Perspective for Oral Antivirals by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors for the Years 2015, 2025 & 2030
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: South Korea Historic Review for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: South Korea 15-Year Perspective for Oral Antivirals by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Rest of Asia-Pacific Historic Review for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Rest of Asia-Pacific 15-Year Perspective for Oral Antivirals by Indication - Percentage Breakdown of Value Sales for Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 15-Year Perspective for Oral Antivirals by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors for the Years 2015, 2025 & 2030
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 15-Year Perspective for Oral Antivirals by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Oral Antivirals Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Oral Antivirals by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Oral Antivirals by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Latin America 15-Year Perspective for Oral Antivirals by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Latin America 15-Year Perspective for Oral Antivirals by Indication - Percentage Breakdown of Value Sales for Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Latin America 15-Year Perspective for Oral Antivirals by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors for the Years 2015, 2025 & 2030
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Latin America 15-Year Perspective for Oral Antivirals by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 206: Argentina Recent Past, Current & Future Analysis for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Argentina Historic Review for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Argentina 15-Year Perspective for Oral Antivirals by Indication - Percentage Breakdown of Value Sales for Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Argentina 15-Year Perspective for Oral Antivirals by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors for the Years 2015, 2025 & 2030
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Argentina Historic Review for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Argentina 15-Year Perspective for Oral Antivirals by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 215: Brazil Recent Past, Current & Future Analysis for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Brazil Historic Review for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Brazil 15-Year Perspective for Oral Antivirals by Indication - Percentage Breakdown of Value Sales for Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 220: Brazil 15-Year Perspective for Oral Antivirals by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors for the Years 2015, 2025 & 2030
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Brazil Historic Review for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 223: Brazil 15-Year Perspective for Oral Antivirals by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 224: Mexico Recent Past, Current & Future Analysis for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Mexico Historic Review for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 226: Mexico 15-Year Perspective for Oral Antivirals by Indication - Percentage Breakdown of Value Sales for Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 229: Mexico 15-Year Perspective for Oral Antivirals by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors for the Years 2015, 2025 & 2030
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Mexico Historic Review for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 232: Mexico 15-Year Perspective for Oral Antivirals by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Rest of Latin America Historic Review for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 235: Rest of Latin America 15-Year Perspective for Oral Antivirals by Indication - Percentage Breakdown of Value Sales for Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 238: Rest of Latin America 15-Year Perspective for Oral Antivirals by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors for the Years 2015, 2025 & 2030
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 241: Rest of Latin America 15-Year Perspective for Oral Antivirals by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Oral Antivirals Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Oral Antivirals by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Oral Antivirals by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 244: Middle East 15-Year Perspective for Oral Antivirals by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 247: Middle East 15-Year Perspective for Oral Antivirals by Indication - Percentage Breakdown of Value Sales for Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 250: Middle East 15-Year Perspective for Oral Antivirals by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors for the Years 2015, 2025 & 2030
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 253: Middle East 15-Year Perspective for Oral Antivirals by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 254: Iran Recent Past, Current & Future Analysis for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Iran Historic Review for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 256: Iran 15-Year Perspective for Oral Antivirals by Indication - Percentage Breakdown of Value Sales for Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 259: Iran 15-Year Perspective for Oral Antivirals by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors for the Years 2015, 2025 & 2030
    • TABLE 260: Iran Recent Past, Current & Future Analysis for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Iran Historic Review for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 262: Iran 15-Year Perspective for Oral Antivirals by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 263: Israel Recent Past, Current & Future Analysis for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Israel Historic Review for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 265: Israel 15-Year Perspective for Oral Antivirals by Indication - Percentage Breakdown of Value Sales for Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 268: Israel 15-Year Perspective for Oral Antivirals by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors for the Years 2015, 2025 & 2030
    • TABLE 269: Israel Recent Past, Current & Future Analysis for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Israel Historic Review for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 271: Israel 15-Year Perspective for Oral Antivirals by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Saudi Arabia Historic Review for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 274: Saudi Arabia 15-Year Perspective for Oral Antivirals by Indication - Percentage Breakdown of Value Sales for Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 277: Saudi Arabia 15-Year Perspective for Oral Antivirals by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors for the Years 2015, 2025 & 2030
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 280: Saudi Arabia 15-Year Perspective for Oral Antivirals by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 281: UAE Recent Past, Current & Future Analysis for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: UAE Historic Review for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 283: UAE 15-Year Perspective for Oral Antivirals by Indication - Percentage Breakdown of Value Sales for Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 286: UAE 15-Year Perspective for Oral Antivirals by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors for the Years 2015, 2025 & 2030
    • TABLE 287: UAE Recent Past, Current & Future Analysis for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: UAE Historic Review for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 289: UAE 15-Year Perspective for Oral Antivirals by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Rest of Middle East Historic Review for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 292: Rest of Middle East 15-Year Perspective for Oral Antivirals by Indication - Percentage Breakdown of Value Sales for Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 295: Rest of Middle East 15-Year Perspective for Oral Antivirals by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors for the Years 2015, 2025 & 2030
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 298: Rest of Middle East 15-Year Perspective for Oral Antivirals by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers for the Years 2015, 2025 & 2030
  • AFRICA
    • Oral Antivirals Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 299: Africa Recent Past, Current & Future Analysis for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Africa Historic Review for Oral Antivirals by Indication - Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 301: Africa 15-Year Perspective for Oral Antivirals by Indication - Percentage Breakdown of Value Sales for Human Immunodeficiency Virus, Hepatitis, Influenza and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Oral Antivirals by Drug Class - Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 304: Africa 15-Year Perspective for Oral Antivirals by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, Reverse Transcriptase Inhibitors and Protease Inhibitors for the Years 2015, 2025 & 2030
    • TABLE 305: Africa Recent Past, Current & Future Analysis for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Africa Historic Review for Oral Antivirals by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 307: Africa 15-Year Perspective for Oral Antivirals by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제